Metraipolis › archive › dc_391bb7984da1
Rosai-Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy — Europe PMC PMID:42306561
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42306561
- DOI
- 10.1093/omcr/omag079
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T11:07:25.138Z
- SHA-256 of the archived text
274ba49e81aa37cad4ded6b09bf71baf3737d8e6f26b93a50619c89410c1ce63- Stable URL of this page
https://metraipolis.com/documento/dc_391bb7984da1
How to cite
Rosai-Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy — Europe PMC PMID:42306561 — Europe PMC (en), https://europepmc.org/article/MED/42306561 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_391bb7984da1 (Metraipolis archive dc_391bb7984da1, sha256 274ba49e81aa37cad4ded6b09bf71baf3737d8e6f26b93a50619c89410c1ce63)
BibTeX
@misc{dc391bb7984da1,
title = {Rosai-Dorfman disease with MAP2K1 mutation: therapeutic response to MEK inhibition after failure of conventional therapy — Europe PMC PMID:42306561},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42306561},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_391bb7984da1; sha256 274ba49e81aa37cad4ded6b09bf71baf3737d8e6f26b93a50619c89410c1ce63},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42306561. Agents can read the archived copy with the MCP tool read_document.